Evidence map›Paper›PMID 41236183›Full record

ArticleSmall methods2025

Characterization of Ligand Binding in Human Serum Albumin from Atomistic Energy Transfer Simulations.

Özge Ergün, Andrea Bertran-Mostazo, Elena Cubero, Carles Galdeano, Carles Curutchet

Abstract read
In one paragraph

Article in Small methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Özge ErgünDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Barcelona, 08028, Spain.ORCID 0000-0003-2340-7279
Andrea Bertran-MostazoDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Barcelona, 08028, Spain.ORCID 0000-0002-7971-6540
Elena CuberoGain Therapeutics Sucursal en España, Barcelona Science Park, Barcelona, 08028, Spain.ORCID 0000-0002-2239-6670
Carles GaldeanoDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Barcelona, 08028, Spain.ORCID 0000-0003-1702-0369
Carles CurutchetDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Barcelona, 08028, Spain.ORCID 0000-0002-0070-1208

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2021SGR00671H2020 Marie Skłodowska-Curie Actions 956314State Research Agency/Spanish Ministry of Science, Innovation and Universities CEX2021-001202-MState Research Agency/Spanish Ministry of Science, Innovation and Universities PID2020-115812GB-I00State Research Agency/Spanish Ministry of Science, Innovation and Universities PID2023-151584NB-I00State Research Agency/Spanish Ministry of Science, Innovation and Universities PRE2019-087468
6 · The paper itself

Abstract

Förster resonance energy transfer (FRET) is a key biophysical method for probing nanometer‑scale distances in biomolecular systems, but its direct application to protein-ligand complexes suffers from substantial biases due to restricted chromophore orientations and the limited validity of the point‑dipole approximation. This study introduces a protocol for identifying binding sites and characterizing ligand coordination modes in situ by combining fluorescence spectroscopy with efficient atomistic simulations based on the TrESP‑MMPol model. The protocol integrates electrostatic potential‑fitted transition charges with a polarizable classical environment, thereby overcoming the orientation and dielectric-screening assumptions inherent to Förster theory. The protocol has been applied to human serum albumin (HSA) and a library of fluorescent small molecules, including known binders of the HSA, accurately reproducing the binding sites of naproxen, carprofen, and indomethacin, and revealing novel binding scenarios for other molecules. The results show that direct comparison of experimental FRET data with atomistically simulated observables enables discrimination of plausible binding models - including the site and binding mode - and avoids systematic errors in distance estimation. The protocol is particularly attractive to examine targets with a single tryptophan, and can also be extended to other targets of interest in drug discovery via site-labelling with unnatural amino acids.

Indexed as

Fluorescence Resonance Energy TransferSerum AlbuminSerum Albumin, HumanBinding SitesHumansLigandsMolecular Dynamics SimulationNaproxenProtein BindingLigandsNaproxenSerum AlbuminSerum Albumin, Humanenergy transferFREThuman serum albuminmolecular dynamicsprotein‐ligand binding

Identifiers

PMID41236183
PMCPMC12716216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.